An exploratory study to evaluate the effect of HPV 16 [human papilloma virus 16] vaccine [verpasep caltespen; SGN-00101] on the reduction of viral load in HPV 16 positive women with persistent viral infection, but low grade disease (ASCUS/LSIL).

Trial Profile

An exploratory study to evaluate the effect of HPV 16 [human papilloma virus 16] vaccine [verpasep caltespen; SGN-00101] on the reduction of viral load in HPV 16 positive women with persistent viral infection, but low grade disease (ASCUS/LSIL).

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs Verpasep caltespen (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Feb 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top